(150) constructed a radiomic prediction vector for lung cancer immunotherapy (LCI-RPV) on the basis of radiomic tumor features from enhanced chest CT scans, CD274 counts in NSCLC patients treated with anti-PD-1/PD-L1 therapy, and RNA expression levels of the PD-L1 protein-coding gene as the response variable. This evidence concerns the gene CD274 and lung cancer.